NF-κB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145
Open Access
- 15 January 2006
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 107 (2) , 827-834
- https://doi.org/10.1182/blood-2005-05-1820
Abstract
NF-κB is a transcription factor that controls the expression of a number of genes important for mediating immune and inflammatory responses. In thisKeywords
This publication has 50 references indexed in Scilit:
- Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015)Journal of Clinical Oncology, 2004
- Phase II Trial of Bortezomib for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Activation of Nuclear Factor κB In vivo Selectively Protects the Murine Small Intestine against Ionizing Radiation-Induced DamageCancer Research, 2004
- In vivo imaging of graft-versus-host-disease in miceBlood, 2004
- The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor BortezomibExperimental Cell Research, 2004
- The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cellsOncogene, 2003
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999
- Structure, Regulation and Function of NF-kappaBAnnual Review of Cell Biology, 1994
- INTERLEUKIN-1 IS A CRITICAL EFFECTOR MOLECULE DURING CYTOKINE DYSREGULATION IN GRAFT VERSUS HOST DISEASE TO MINOR HISTOCOMPATIBILITY ANTIGENS1Transplantation, 1993
- Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease.The Journal of Experimental Medicine, 1992